Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Abstract
Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis. Advantages of this triazole include the availability of a water-soluble intravenous formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults. A randomized, double-blind comparison clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole. An open-label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amphotericin B and posaconazole. In patients in these studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few serious adverse effects, and had fewer drug-drug interactions than those noted with voriconazole. As clinical experience increases, the role of this new triazole in the treatment of invasive fungal infections will be better defined.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
New-generation triazoles have significant drug-drug interactions, adverse effects, and cross-resistance that limit their clinical applicability.
“New-generation triazoles, such as posaconazole and voriconazole, have the advantages of extended-spectrum activity and availability for both oral and intravenous medication; however, significant drug-drug interactions, adverse effects, and cross-resistance limit their clinical applicability (6).”
From Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review (2023) · cites this paper as [6]
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561 · see citing works
Molecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441 · see citing works
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271 · see citing works
Triazole Resistance in Aspergillus spp.: A Worldwide Problem?
Rivero-Menendez, O., Alastruey-Izquierdo, A., Mellado, E., & Cuenca-Estrella, M. (2016) · Journal of Fungi · doi:10.3390/jof2030021 · Cited by 142 · see citing works
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124 · see citing works
Development and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85 · see citing works
Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
Hayes, G., & Novak-Frazer, L. (2016) · Journal of Fungi · doi:10.3390/jof2020018 · Cited by 77 · see citing works
Trends in antifungal use in US hospitals, 2006–12
Vallabhaneni, S., Baggs, J., Tsay, S., Srinivasan, A. R., Jernigan, J. A., & Jackson, B. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky270 · Cited by 45 · see citing works
Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review
Qin, Y., Wang, J., Lv, Q., & Han, B. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00003-23 · Cited by 38 · see citing works
“tions, adverse effects, and cross-resistance limit their clinical applicability (6).”
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8 · see citing works
- Authors
- Miceli, M. H., & Kauffman, C. A.
- Affiliations
- Michigan Medicine (US)
- VA Ann Arbor Healthcare System (US)
- Corresponding author
- Miceli, Marisa H.
- ORCID
- Miceli, Marisa H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-15
- Volume
- 61
- Issue
- 10
- Pages
- 1558-1565
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2114954734
- Cited by
- 338
- References
- 1
- Citations by year
- 2026: 12 · 2025: 38 · 2024: 26 · 2023: 25 · 2022: 23 · 2021: 31 · 2020: 25 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 35 · 2015: 7
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- isavuconazole, triazole antifungals, invasive aspergillosis, invasive mucormycosis, dimorphic fungi, drug-drug interactions, pharmacokinetics, oral bioavailability, adverse effects, invasive fungal infections
- MeSH terms
- Antifungal Agents, Humans, Mucormycosis, Nitriles, Pyridines, Triazoles, Randomized Controlled Trials as Topic, Treatment Outcome, Invasive Pulmonary Aspergillosis, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
